SCHEMBL19684746

SCHEMBL19684746

CCCCOc1cc(Br)cc2c1C(=O)N(C(=O)OC(C)(C)C)CCO2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.34
ATM Q13315 2/20 0.33
USP30 Q70CQ3 1/20 0.33
NAAA Q02083 1/20 0.33
RORA P35398 1/20 0.32
NR5A1 Q13285 1/20 0.32
GPR119 Q8TDV5 1/20 0.32
PDE4D Q08499 2/20 0.31
MAPT P10636 2/20 0.31
TP53 P04637 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
BUB1 O43683 1/20 0.31
PDE4A P27815 1/20 0.31
PDE4B Q07343 1/20 0.31
PDE4C Q08493 1/20 0.31
GRM5 P41594 1/20 0.31
THRB P10828 1/20 0.31
KEAP1 Q14145 1/20 0.31
NFE2L2 Q16236 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19667443 0.84 GRM5 (0.42) USP30NAAAMAPTBUB1GRM5
SCHEMBL19679349 0.81 USP30 (0.37) ATMUSP30GPR119MAPTSMN1; SMN2
SCHEMBL19684711 0.79 PIK3CD (0.36) USP30GPR119PDE4DSMN1; SMN2PDE4A
SCHEMBL1093600 0.72 GRM5 (0.47) USP30SMN1; SMN2GRM5
SCHEMBL29046812 0.70 TLR9 (0.40) USP30MAPTSMN1; SMN2
SCHEMBL19684745 0.70 CNR2 (0.35) CNR2RORANR5A1PDE4DMAPT
SCHEMBL5276056 0.69 USP30 (0.50) USP30SMN1; SMN2LMNA
SCHEMBL21597039 0.69 GRM5 (0.46) CNR2NAAAMAPTSMN1; SMN2GRM5
SCHEMBL19684748 0.69 PRKCA (0.36) CNR2MAPTTP53PDE4B
SCHEMBL19684931 0.68 CSF1R (0.39) GPR119PDE4DSMN1; SMN2PDE4APDE4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS PFIZER INC. (US) 2017-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170348313-A1 SUBSTITUTED CARBONUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS DUT, NCL, TYMP CNR2 4127/4885ATM 1838/4885USP30 2696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.